公开(公告)号：EP1761262B1

公开(公告)日：2008-12-03

申请号：EP05756055.9

申请日：2005-06-17

申请人： Neuropharma, S.A.

发明人： MARTÍNEZ GIL, Ana ,  ALONSO GORDILLO, Diana ,  DORRONSORO DÍAZ, Isabel ,  GARCÍA PALOMERO, Esther ,  DE AUSTRIA DE LUQUE, Celia ,  USÁN EGEA, Paola ,  DEL MONTE MILLÁN, María ,  MEDINA PADILLA, Miguel

IPC分类号： A61K31/42 ,  C07D261/20

CPC分类号： C07D261/20

摘要： The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.

公开(公告)号：EP1761262A1

公开(公告)日：2007-03-14

申请号：EP05756055.9

申请日：2005-06-17

申请人： Neuropharma, S.A.

发明人： MARTÍNEZ GIL, Ana ,  ALONSO GORDILLO, Diana ,  DORRONSORO DÍAZ, Isabel ,  GARCÍA PALOMERO, Esther ,  DE AUSTRIA DE LUQUE, Celia ,  USÁN EGEA, Paola ,  DEL MONTE MILLÁN, María ,  MEDINA PADILLA, Miguel

IPC分类号： A61K31/42 ,  C07D261/20

CPC分类号： C07D261/20

摘要： The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.

公开(公告)号：EP1689730A1

公开(公告)日：2006-08-16

申请号：EP04819730.5

申请日：2004-12-02

申请人： Neuropharma, S.A.

发明人： ALONSO GORDILLO, Diana ,  DORRONSORO DÍAZ, Isabel ,  MARTINEZ GIL, Ana ,  PANIZO DEL PLIEGO, Gema ,  FUERTES HUERTA, Ana ,  PÉREZ PUERTO, Ma José ,  MARTÍN APARICIO, Ester ,  PÉREZ NAVARRO, Darío ,  MEDINA PADILLA, Miguel

IPC分类号： C07D307/60 ,  C07D307/62 ,  A61K31/365 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00

CPC分类号： C07D407/06

摘要： The present invention provides the use of a compound of formula (I); wherein: n is 0, 1, 2, or 3, the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds; R, and R’ are independently selected from hydrogen, alkyl, aryl, -OH, -OR’’ -SH, -SR’’- NH’’ -NHR', =O, =NH, =NR'; R' is independently selected frorn alkyl, aryl, in the preparation of a medicament for the treatment of a disease requiring a GSK-3 inhibitor. Also provided is a compound of formula (II); wherein n is 0, 1, 2, or 3 the bonds shown with the dashed lines are saturated, or unsaturated with one or more double bonds. Also provided are methods of treating chronic neurodegenerative conditions.